Anthracyclines News and Research

RSS

Great news for breast cancer patients

In encouraging new study results researchers say that modern treatments have significantly boosted the 15-year survival rate for breast cancer, and even better news is that they have also found that drug and hormonal therapies effectively cure many women, rather than simply delaying the recurrence of disease.

12 May 2005

Combination chemotherapy shows small survival benefit in advanced stomach cancer

Patients with advanced stomach cancer have the best chance of prolonging their survival with a combination of chemotherapies instead of just one, according to a new review of previous studies.

19 Apr 2005

Cell Therapeutics receives Fast Track Designation for Pixantrone, treatment for aggressive non-Hodgkin's lymphoma

Cell Therapeutics, Inc. has received fast track designation from the U.S. Food and Drug Administration (FDA) for pixantrone, a novel anthracenedione, being investigated for the potential treatment of relapsed, aggressive non-Hodgkin's lymphoma (NHL).

12 Jul 2004

Gemcitabine/paclitaxel combination helps breast cancer patients live longer

Breast cancer patients with advanced disease live longer when treated with a new drug, gemcitabine, in combination with paclitaxel, a traditional drug, according to results of a landmark global phase III study

9 Jun 2004

Gemcitabine may help breast cancer patients with advanced disease live longer

6 Jun 2004

First patient dosed with Tesmilifene in pivotal breast cancer study

YM BioSciences Inc., the cancer drug development company, today announced that the first patient has been dosed in its 700 patient Phase III registration trial.

31 Mar 2004